Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent

NEWARK, Calif., July 18, 2016 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute the Inter Partes Review (IPR) petition filed by Rosellini Scientific, LLC with respect to U.S. Patent No. 7,994,364 (the "'364 Patent") with respect to all patent claims subject of the petition.  The '364 Patent is listed for the company's NUCYNTA® (tapentadol) and NUCYNTA® ER (tapentadol extended release tablets) products in the FDA's Orange Book.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to the timing of a decision in the ANDA litigation related to its NUCYNTA and NUCYNTA ER products, as well as other risks detailed in the company's Securities and Exchange Commission filings, including the company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. There can be no assurance of a positive outcome in such litigation, or other assurance that actual results will be as expected or anticipated.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.

Investor Contact:

Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]

SOURCE Depomed, Inc.

Related Links

http://www.depomed.com